Summary
Following a week of racemic mexiletine HCl at 200 mg tid (2×100 mg capsules), stereoselective aliphatic hydroxylation was studied in eight Chagasic women with chronic ventricular arrhythmias (52–67 yrs) with no history of renal or hepatic diseases. Blood samples were collected at dose interval up to 24 h of drug administration. Plasma concentrations of R(−) and S(+) mexiletine (MEX) and its metabolite hydroxymethylmexiletine (HMM) were determined by HPLC after derivatization with chiral reagent. The differences between R(−) and S(+) enantiomers were compared by paired t-test. Results are mean (95% CI). The following differences (p<0.05) between R(−) and S(+) enantiomers, respectively, were found: MEX AUCss 0−8 2.34 (1.84–2.85) vs 2.55 (1.97–3.13) μg.ml−1.h−1; MEX CL/f 11.27 (7.77–14.77) vs 10.46 (7.18–13.74) ml.min−1.Kg−1; HMM Cmax 38.26 (24.3–52.22) vs 16.73 (10.1–23.29)ng.ml−1; HMM Tmax 4.71 (2.67–6.76) vs 3.29 (1.24–5.33) h and HMM AUCss 0–8 253.50 (165.39–341.61) vs 103.70 (69.51–137.90)ng.ml−1.h−1. The AUCss 0–8 ratio R(−)/S(+) for MEX was 0.93 (0.87–0.98) while for HMM was 2.50 (2.16–2.85). Distribution of MEX and HMM enantiomers were not significantly different. In this study we demonstrate that kinetic disposition of mexiletine exhibits stereoselectivityin vivo and that aliphatic hydroxylation is favored for R(−) mexiletine in Chagasic women with ventricular arrhythmias.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abolfathi Z., Fiset C., Gilbert M., Moerike K., Bélanger P.M., Turgeon J. (1993): Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans. J. Pharmacol. Exp. Ther., 266, 1196–201.
Broly F., Vandamme N., Libersa C., Lhermitte M. (1991): The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br. J. Clin. Pharmac., 32, 459–66.
Bruno R., Santoni Y., Iliadis A., Djiane P., Serradimigni A., Cano J.P. (1992): Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single- and multiple-dose administration of a sustained-release mexiletine formulation. Biopharmaceutics & Drug Disposition, 13, 481–93.
Fieger H., Wainer I.W. (1993): Direct analysis of the enantiomers of mexiletine and its metabolites in plasma and urine using an HPLC-CSP. J. Pharm. Miomed. Anal., 11, p. 1173–9.
Grech-Belanger O., Turgeon J, Gilbert M. (1986): Stereoselective disposition of mexiletine in man. Br. J. Clin. Pharmac, 21, 481–7.
Haedo A.H., Chiale P.A., Bandieri J.D., Lázzari J.O., Elizari M.V., Rosenbaum M.B. (1986): Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms J. Am. Coll. Cardiol., 7, p. 114–20.
Igwemezie L., Kerr C.R., McErlane K.M. (1989): The pharmacokinetics of the enantiomers of mexiletine in humans. Xenobiotica, 19, p. 677–82.
Kwok D.W., Kerr C.R., McErlane K.M. (1995): Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of thein vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. Xenobiotica, 25, p. 1127–42.
Lanchote V.L., Bonato P.S., Dreossi, S.A.C., Gonçalves P.V.B., Cesarino E.J., Bertucci C. (1996): HPLC determination of mexiletine enantiomers in plasma using direct and indirect enantioselective separations, (in press).
Levy-Prades R., Philip F., Danays T., Serradimigni A., Cano J.P. (1987): Pharmacocinétique de la mexiltine et de son métabolite hydroxyméthyle apres administration intramusculaire et intraveineuse de mexiltine chez le sujet sain. Therapie, 42, 3–7.
Lledó R. Abrams S.M.L., Johnston A., Patel M., Pearson R.M., Turner P. (1993): Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. Eur. J. Clin. Pharmacol, 44, 63–7.
McErlane K.M., Igwemezie L., Kerr C.R. (1987): Stereoselective serum protein binding of mexiletine enantiomers in man. Res. Commun. Chem. Pathol. Pharmacol., 56, p. 141–5.
Monk J.P., Brogden R.N. (1990): Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs, 40, p. 374–411.
Ohashi K., Ebihara A., Hashimoto T., Hosoda S., Kondo K., Oka T. (1984): Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. Arzneim-Forsch./Drug Res., 34, 503–7.
Paczkowski D., Sadowski Z., Filipek M., Kolinski P. (1990): Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. Pol. J. Pharmacol. Pharm., 42, 365–76.
Turgeon J., Uprichard A.C.G., Belanger P.M., Harron D.W.G., Grech-Belanger O. (1991): Resolution and electrophysiological effects of mexiletine enantiomers. J. Pharm. Pharmacol., 43, 630–5.
Ueno K., KawaguchI Y., Tanaka K. (1993): Pharmacokinetics of mexiletine in middle-aged and elderly patients. Clinical Pharmacy, 12, 768–73.
Vandamme N., Broly F., Libersa C., Courseau C., Lhermitte M. (1993): Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6 — a preliminary report. J. Cardiovasc. Pharmacol., 21, 77–83.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lanchote, V.L., Cesarino, E.J., Santos, V.J. et al. Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. European Journal of Drug Metabolism and Pharmacokinetics 23, 259–266 (1998). https://doi.org/10.1007/BF03189349
Issue Date:
DOI: https://doi.org/10.1007/BF03189349